Ads
related to: squamous cell carcinoma treatment- Patient Quality of Life
View Patient Quality of Life Data
After Undergoing a GBM Treatment.
- What is TTFields Therapy?
Access Information on How TTFields
are Being Used for GBM Treatment.
- View 5-Year Efficacy Data
TTFields Long-Term Efficacy Data is
Available. Click to Learn More.
- GBM Patient Resources
Download Brochures and Treatment
Support Docs for Your GBM Patients.
- GBM Patient Buddy Program
GBM Patients Can Sign Up & Connect
to Experienced Users & Caregivers.
- Video Library
Watch Videos from Experts & Hear
GBM Patient Treatment Experiences.
- Patient Quality of Life
perrinnaturals.com has been visited by 10K+ users in the past month
Search results
BeiGene's (BGNE) Shares Surge 32% in a Month: Here's Why
Zacks via Yahoo Finance· 7 days agoBeigene's (BGNE) shares surge 32% in a month due to the label expansion of one of its key oncology...
Galectin Therapeutics (NASDAQ:GALT) Stock Price Passes Above Two Hundred Day Moving Average of $2.25
ETF DAILY NEWS· 6 days agoGalectin Therapeutics Inc. (NASDAQ:GALT – Get Free Report)’s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.25 and ...
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual...
FOX 59 Indianapolis· 3 days agoMabwell (688062.SH), an innovation-driven biopharmaceutical company, announced the data and latest...
Galectin Therapeutics (NASDAQ:GALT) Upgraded to “Hold” by StockNews.com
ETF DAILY NEWS· 6 days agoGalectin Therapeutics (NASDAQ:GALT – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday. Separately, HC ...
Potential Precursor Lesion to Adrenal Tumors Identified
Medscape· 4 days agoCortisol-producing adenomas (CPAs) are preceded by the development of steroids-producing nodules...
ASCO: Early peek at Merus' bispecific cancer data lives up to investors' expectations
FierceBiotech· 3 days agoAnalysts have hailed Merus’ latest data drop in head and neck cancer as meeting investors’...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 4 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive new results from an ongoing Phase 1/2 trial evaluating its first-in-class costimulatory bispecific antibody, REGN7075 ...
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Zacks· 3 days agoThe phase I/II first-in-human, open-label study is evaluating REGN7075, in combination with oncology drug Libtayo (cemiplimab). The study is currently enrolling patients with metastatic and ...
Small Business - The Roanoke-Chowan News-Herald | The Roanoke-Chowan News-Herald
Roanoke-Chowan News-Herald· 4 days agoCHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells (Tregs) was observed and depletion was maintained
How age affects laryngeal cancer rates, treatment, and more
Medical News Today· 6 days agoLaryngeal cancer is more common in older adults than in younger people. Laryngeal cancer is much...